NEW YORK, April 22 /PRNewswire-FirstCall/ -- Emerging infectious diseases pose an urgent global threat that endangers the economic survival of the poorest countries on Earth and the growth and development of many more, according to a panel of experts presenting at the Milken Institute Global Conference 2005 in Los Angeles, CA. The academic and industry leaders at the Bioaccelerate-sponsored panel, titled Emerging Diseases: Interdependence and Innovation, claimed that international efforts by governments, private aid organizations, academia and the pharmaceutical industry have been largely unsuccessful in addressing the enormous challenges posed by emerging infectious diseases.
Speakers for the breakfast panel included Greg Simon, President, FasterCures/The Center for Accelerating Medical Solutions; Michael J. Ryan, M.D., Director, CSR Office of Alert and Response Operations, Communicable Diseases, World Health Organization, Geneva; and Frank Armstrong, M.D., CEO of Bioaccelerate.
To address this growing issue, Bioaccelerate Holdings Inc. (OTC Bulletin Board: BACLE) announced the formation of Candid Pharmaceuticals, which is focused on novel approaches to addressing the development and commercialization of drugs to treat emerging infectious diseases. Through its Candid Pharmaceuticals subsidiary, Bioaccelerate is bringing its business model to bear on emerging and neglected diseases. Candid is working with non- government organizations and Government agencies to identify solutions to a range of diseases, including Malaria, TB, HIV (AIDS), Hepatitis, Leishmaniasis, Chagas Disease, HAT and respiratory infections. A number of compounds that address HIV (AIDS), Hepatitis C, Leishmaniasis, and Chagas Disease are under review. Bruce Murdoch, Acting CEO of Candid Pharmaceuticals, stated, “We believe that by applying Bioaccelerate’s business model, we can help bridge the gap between finding discoveries that could lead to new, cost-effective drugs and delivering them to patients in on a global scale. We look forward to working on this important initiative in cooperation with our partners and other stakeholders.”
Surmounting the significant hurdles to a more effective global response to emerging infectious diseases as well as infectious disease outbreaks will require an unprecedented level of cooperation among academia, international aid organizations, governments and pharmaceutical companies, as well as substantially greater financial resources. New approaches and innovative drug development and commercialization strategies, such as Bioaccelerate’s model to enable development of promising new drugs, are a vital part of this critical and essential effort.
About Bioacclerate Holdings Inc.
Bioaccelerate Holdings Inc. (BACLE.OB) is a pharmaceutical development organization (“PDO”) that seeks to acquire, develop and commercialize novel pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate uses its broad network of academic, industry and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries. The company holds majority equity interests in 10 biopharmaceutical companies, three of which are public, and holds minority interests in four biopharmaceutical companies, two of which are public. The company also holds a minority equity interest in a public nanotechnology company. Bioaccelerate’s strategy relies on its development network for research, clinical development and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin Board under the symbol “BACLE.OB.” For more information on Bioaccelerate, visit the company’s website at http://www.bioaccelerate.com/.
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general or Bioaccelerate’s compounds under development in particular; the potential failure of Bioaccelerate’s compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioaccelerate’s compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioaccelerate’s business, structure or projections; the development of competing products; uncertainties related to Bioaccelerate’s dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under Bioaccelerate’s prior name Mobile Design Concepts, Inc. Bioaccelerate disclaims any obligation to update these forward-looking statements.
Contacts: Bioaccelerate Holdings Inc. Christopher O’Toole Senior Vice President 212-332-4387 Matthew Haines (Investors) Vice President Noonan Russo 212-845-4235 Emily Poe (Media) Vice President Noonan Russo 212-845-4266
Bioaccelerate Holdings Inc.
CONTACT: Christopher O’Toole, Senior Vice President of BioaccelerateHoldings Inc., +1-212-332-4387; or Matthew Haines (Investors), Vice President,+1-212-845-4235, or Emily Poe (Media), Vice President, +1-212-845-4266, bothof Noonan Russo, for Bioaccelerate Holdings
Web Site: http://www.bioaccelerate.com/
